D2 dopamine receptor gene expression in the rat striatum during ontogeny: an in situ hybridization study

Behavioral and Neuroanatomical Consequences of Cell-Type Specific Loss of Dopamine D2 Receptors in the Mouse Cerebral Cortex

Developmental dysregulation of dopamine D2 receptors (D2Rs) alters neuronal migration, differentiation, and behavior and contributes to the psychopathology of neurological and psychiatric disorders. The current study is aimed at identifying how cell-specific loss of D2Rs in the cerebral cortex may impact neurobehavioral and cellular development, in order to better understand the roles of this receptor in cortical circuit formation and brain disorders. We deleted D2R from developing cortical GABAergic interneurons (Nkx2.1-Cre) or from developing telencephalic glutamatergic neurons (Emx1-Cre). Conditional knockouts (cKO) from both lines, Drd2^fl/fl, Nkx2.1-Cre⁺ (referred to as GABA-D2R-cKO mice) or Drd2^fl/fl, Emx1-Cre⁺ (referred to as Glu-D2R-cKO mice), exhibited no differences in simple tests of anxiety-related or depression-related behaviors, or spatial or nonspatial working memory. Both GABA-D2R-cKO and Glu-D2R-cKO mice also had normal basal locomotor activity, but GABA-D2R-cKO mice expressed blunted locomotor responses to the psychotomimetic drug MK-801. GABA-D2R-cKO mice exhibited improved motor coordination on a rotarod whereas Glu-D2R-cKO mice were normal. GABA-D2R-cKO mice also exhibited spatial learning deficits without changes in reversal learning on a Barnes maze. At the cellular level, we observed an increase in PV+ cells in the frontal cortex of GABA-D2R-cKO mice and no noticeable changes in Glu-D2R-cKO mice. These data point toward unique and distinct roles for D2Rs within excitatory and inhibitory neurons in the regulation of behavior and interneuron development, and suggest that location-biased D2R pharmacology may be clinically advantageous to achieve higher efficacy and help avoid unwanted effects.

Neuronal Circuit-Based Computer Modeling as a Phenotypic Strategy for CNS R&D

With the success rate of drugs for CNS indications at an all-time low, new approaches are needed to turn the tide of failed clinical trials. This paper reviews the history of CNS drug Discovery over the last 60 years and proposes a new paradigm based on the lessons learned. The initial wave of successful therapeutics discovered using careful clinical observations was followed by an emphasis on a phenotypic target-agnostic approach, often leading to successful drugs with a rich pharmacology. The subsequent introduction of molecular biology and the focus on a target-driven strategy has largely dominated drug discovery efforts over the last 30 years, but has not increased the probability of success, because these highly selective molecules are unlikely to address the complex pathological phenotypes of most CNS disorders. In many cases, reliance on preclinical animal models has lacked robust translational power. We argue that Quantitative Systems Pharmacology (QSP), a mechanism-based computer model of biological processes informed by preclinical knowledge and enhanced by neuroimaging and clinical data could be a new powerful knowledge generator engine and paradigm for rational polypharmacy. Progress in the academic discipline of computational neurosciences, allows one to model the effect of pathology and therapeutic interventions on neuronal circuit firing activity that can relate to clinical phenotypes, driven by complex properties of specific brain region activation states. The model is validated by optimizing the correlation between relevant emergent properties of these neuronal circuits and historical clinical and imaging datasets. A rationally designed polypharmacy target profile will be discovered using reverse engineering and sensitivity analysis. Small molecules will be identified using a combination of Artificial Intelligence methods and computational modeling, tested subsequently in heterologous cellular systems with human targets. Animal models will be used to establish target engagement and for ADME-Tox, with the QSP approach complemented by in vivo preclinical models that can be further refined to increase predictive validity. The QSP platform can also mitigate the variability in clinical trials with the concept of virtual patients. Because the QSP platform integrates knowledge from a wide variety of sources in an actionable simulation, it offers the possibility of substantially improving the success rate of CNS R&D programs while, at the same time, reducing both cost and the number of animals.

Maternal immune activation alters sensitivity to action-outcome contingency in adult rat offspring

Epidemiological studies have provided convincing evidence for a role of maternal immune activation in the pathogenesis of neurodevelopmental disorders such as autism and schizophrenia. In recent years, several research groups have capitalised on this discovery and developed animal models such as the maternal immune activation (MIA) model that emulates many phenotypes characteristic of disorders such as schizophrenia. In the present series of experiments we used the MIA model to examine motivation, a core component of the negative symptomatology in schizophrenia. Contrary to what we expected, in the progressive ratio task, which assesses an animals' willingness to work for a reward under increasing effort requirements, we found that MIA rats appeared more motivated than controls. Subsequent tests showed that this seemingly enhanced motivation was not due to an overall increase in responding, nor due to enhanced attribution of incentive salience to reward associated responses. Instead, we found that the increased willingness to work exhibited by MIA animals was due to an inability to detect changes in the contingency between their behaviour and the resulting rewarding outcome. With regard to motivation, the experiments reported here are the first to subject the MIA model to a rigorous experimental analysis of behaviour by parsing underlying processes that give rise to the overt symptoms in psychiatric disease.

The non-human primate striatum undergoes marked prolonged remodeling during postnatal development

We examined the postnatal ontogeny of the striatum in rhesus monkeys (Macaca mulatta) to identify temporal and spatial patterns of histological and chemical maturation. Our goal was to determine whether this forebrain structure is developmentally static or dynamic in postnatal life. Brains from monkeys at 1 day, 1, 4, 6, 9, and 12 months of age (N = 12) and adult monkeys (N = 4) were analyzed. Nissl staining was used to assess striatal volume, cytoarchitecture, and apoptosis. Immunohistochemistry was used to localize and measure substance P (SP), leucine-enkephalin (LENK), tyrosine hydroxylase (TH), and calbindin D28 (CAL) immunoreactivities. Mature brain to body weight ratio was achieved at 4 months of age, and striatal volume increased from ∼1.2 to ∼1.4 cm(3) during the first postnatal year. Nissl staining identified, prominently in the caudate nucleus, developmentally persistent discrete cell islands with neuronal densities greater than the surrounding striatal parenchyma (matrix). Losses in neuronal density were observed in island and matrix regions during maturation, and differential developmental programmed cell death was observed in islands and matrix regions. Immunohistochemistry revealed striking changes occurring postnatally in striatal chemical neuroanatomy. At birth, the immature dopaminergic nigrostriatal innervation was characterized by islands enriched in TH-immunoreactive puncta (putative terminals) in the neuropil; TH-enriched islands aligned completely with areas enriched in SP immunoreactivity but low in LENK immunoreactivity. These areas enriched in SP immunoreactivity but low in LENK immunoreactivity were identified as striosome and matrix areas, respectively, because CAL immunoreactivity clearly delineated these territories. SP, LENK, and CAL immunoreactivities appeared as positive neuronal cell bodies, processes, and puncta. The matrix compartment at birth contained relatively low TH-immunoreactive processes and few SP-positive neurons but was densely populated with LENK-immunoreactive neurons. The nucleus accumbens part of the ventral striatum also showed prominent differences in SP, LENK, and CAL immunoreactivities in shell and core territories. During 12 months of postnatal maturation salient changes occurred in neurotransmitter marker localization: TH-positive afferents densely innervated the matrix to exceed levels of immunoreactivity in the striosomes; SP immunoreactivity levels increased in the matrix; and LENK-immunoreactivity levels decreased in the matrix and increased in the striosomes. At 12 months of age, striatal chemoarchitecture was similar qualitatively to adult patterns, but quantitatively different in LENK and SP in caudate, putamen, and nucleus accumbens. This study shows for the first time that the rhesus monkey striatum requires more than 12 months after birth to develop an adult-like pattern of chemical neuroanatomy and that principal neurons within striosomes and matrix have different developmental programs for neuropeptide expression. We conclude that postnatal maturation of the striatal mosaic in primates is not static but, rather, is a protracted and dynamic process that requires many synchronous and compartment-selective changes in afferent innervation and in the expression of genes that regulate neuronal phenotypes.

Drosophila Dopamine2-like receptors function as autoreceptors

Dopaminergic signaling pathways are conserved between mammals and Drosophila and D2 receptors have been identified in Drosophila. However, it has not been demonstrated whether Drosophila D2 receptors function as autoreceptors and regulate the release of dopamine. The goal of this study was to determine if Drosophila D2 receptors act as autoreceptors by probing the extent to which D2 agonists and antagonists affect evoked dopamine release. Fast-scan cyclic voltammetry was used to measure stimulated dopamine release at a carbon-fiber microelectrode implanted in an intact, larval Drosophila nervous system. Dopamine release was evoked using 5-second blue light stimulations that open Channelrhodopsin-2, a blue light activated cation channel that was specifically expressed in dopaminergic neurons. In mammals, administration of a D2 agonist decreases evoked dopamine release by increasing autoreceptor feedback. Similarly, we found that the D2 agonists bromocriptine and quinpirole decreased stimulated dopamine release in Drosophila. D2 antagonists were expected to increase dopamine release and the D2 antagonists flupenthixol, butaclamol, and haloperidol did increase stimulated release. Agonists did not significantly modulate dopamine uptake although the modulatory effects of D2 drugs on release were affected by prior administration of the uptake inhibitor nisoxetine. These results demonstrate that the D2 receptor functions as an autoreceptor in Drosophila. The similarities in dopamine regulation validate Drosophila as a model system for studying the basic neurobiology of dopaminergic signaling.

Dopamine, cocaine and the development of cerebral cortical cytoarchitecture: a review of current concepts

Exposure of the developing fetus to cocaine produces lasting adverse effects on brain structure and function. Animal models show that cocaine exerts its effects by interfering with monoamine neurotransmitter function and that dopamine is cocaine's principal monoamine target in the fetal brain. This review will examine the role of dopamine receptor signaling in the regulation of normal development of the cerebral cortex, the seat of higher cognitive functions, and discuss whether dopamine receptor signaling mechanisms are the principal mediators of cocaine's deleterious effects on the ontogeny of cerebral cortical cytoarchitecture.

Ontogeny and dopaminergic regulation in brain of Ras homolog enriched in striatum (Rhes)

Rhes is one of several signaling molecules preferentially expressed in the striatum. This GTP-binding protein affects dopamine-mediated signaling and behavior. Denervating the striatum of its dopaminergic inputs in adulthood reduces rhes mRNA expression. Here we show that dopamine depletion in adult rats by 6-hydroxydopamine caused a significant decrease in striatal Rhes protein levels as measured by Western blotting. The role of dopamine input on rhes mRNA induction during ontogeny was also examined. Rhes mRNA was measured on postnatal days 4, 6, 8, 10, 15, and 24 with in situ hybridization to determine its normal ontogeny. Signal in striatum was detectable, but very low, on postnatal day 4 and increased gradually to peak levels at days 15 and 24. Outside of the striatum, rhes mRNA was expressed at high levels in hippocampus and cerebellum during the postnatal period. Hippocampal signal was initially highest in CA3 and dentate gyrus, but shifted to higher expression in CA1 by the late postnatal period. Several other nuclei showed low levels of rhes mRNA during ontogeny. Depletion of dopamine by 6-hydroxydopamine injection on postnatal day 4 did not affect the ontogenetic development of rhes mRNA, such that expression did not differ statistically in lesioned versus vehicle-treated animals tested in adulthood. These findings suggest that although dopamine input is not necessary for the ontogenetic development of rhes mRNA expression, changes in both rhes mRNA and Rhes protein are integral components of the response of the adult striatum to dopamine depletion.

Dopamine receptor mRNA and protein expression in the mouse corpus striatum and cerebral cortex during pre- and postnatal development

The outcome of dopaminergic signaling and effectiveness of dopaminergic drugs depend on the relative preponderance of each of the five dopamine receptors in a given brain region. The separate contribution of each receptor to overall dopaminergic tone is difficult to establish at a functional level due to lack of receptor subtype specific pharmacological agents. A surrogate for receptor function is receptor protein or mRNA expression. We examined dopamine receptor mRNA expression by quantitative reverse transcription real-time PCR in the striatum, globus pallidus, frontal cortex and cingulate cortex of embryonic and postnatal mice. Samples of each region were collected by laser capture microdissection. D1- and D2-receptor mRNAs were the most abundant in all the regions of the mature brain. The D1-receptor was predominant over the D2-receptor in the frontal and cingulate cortices whereas the situation was reversed in the striatum and globus pallidus. In the proliferative domains of the embryonic forebrain, D3-, D4- and D5-receptors were predominant. In the corpus striatum and cerebral cortex, the D3- and D4-receptors were the only receptors that showed marked developmental regulation. By analyzing D1 receptor protein expression, we show that developmental changes in mRNA expression reliably translate into changes in protein levels, at least for the D1-receptor.

Prenatal ethanol preferentially enhances reactivity of the dopamine D1 but not D2 or D3 receptors in offspring

Reports of prenatal ethanol (ETOH) effects on the dopamine system are inconsistent. In an attempt to clarify this issue, dams were given 35% ethanol-derived calories as the sole nutrient source in a liquid diet from the 10th through the 20th day of gestation (ETOH). Controls were pair-fed (PF) an isocaloric liquid diet or given ad libitum access to laboratory chow (LC). Prenatal exposure to both liquid diets reduced body weight of offspring relative to LC controls, more so for ETOH than for PF exposure. Prenatal ETOH also decreased litter size and viability, relative to both LC and PF control groups. On postnatal days 21-23, male and female offspring were given an injection of saline vehicle or one of eight specific dopamine receptor agonists or antagonists. Immediately after injection subjects were placed in individual observation cages, and over the following 30 min, eight behaviors (square entries, grooming, rearing, circling, sniffing, yawning, head and oral movements) were observed and quantified. No prenatal treatment effects on drug-induced behaviors were observed for dopamine D2 (Apomorphine, DPAT or Quinpirole) or D3 (PD 152255, Nafadotride, Apo or Quin effects on yawning) receptor agonists or antagonists, or for the vehicle control. In contrast, prenatal treatment effects were seen with drugs affecting the dopamine D1 receptor. Both D1 agonists (SKF 38393) and antagonists (SCH 23390 and high doses of spiperone) altered behaviors, especially oral and sniffing behaviors, in a manner which suggested enhanced dopamine D1 drug sensitivity in both ETOH and PF offspring relative to LC controls. These results suggest that at this age, both sexes experience a prenatal undernutrition-linked increase in the behavioral response to dopamine D1 agonists and antagonists, which can be intensified by gestational exposure to alcohol.

Effect of prenatal haloperidol exposure on behavioral alterations in rats

Pregnant Charles-Foster rats were exposed to haloperidol (HAL), a neuroleptic drug that binds to and blocks dopamine (DA) receptor subtypes at a dose of 2.5 mg/kg body weight (intraperitoneally) from Gestation Day (GD) 12 to 20. The animals from both treated as well as vehicle control groups were allowed to deliver on GD 21. The offspring culled at birth on the basis of sex and weight were subjected to behavioral tests at the age of 8 weeks. The HAL-treated rat offspring showed a significant increase in anxiogenic behavior on the open field, elevated plus-maze and elevated zero-maze tests when compared with the vehicle-treated (control) rat offspring of the same age group. These findings suggest that prenatal exposure to HAL during a critical period of brain development leaves a lasting imprint on the brain, resulting in abnormal anxiety states, possibly through dopaminergic neurotransmission mechanisms.

Developmental expression of the zinc finger transcription factor DRRF (dopamine receptor regulating factor)

Dopamine receptor regulating factor (DRRF) is a novel transcription factor with unique anatomical distribution and functional properties, suggesting its importance in regulating dopaminergic neurotransmission. To gain insight into the in vivo function of this factor during embryogenesis, we studied its distribution at embryonic days E8-E16 in the mouse using in situ hybridization. DRRF mRNA is expressed uniquely during development at all time points tested with high levels observed at E12, E14 and E16 in various tissues. DRRF expression is also found in particular brain regions, such as the neopallial cortex, olfactory lobe and corpus striatum. This pattern of DRRF distribution during embryogenesis overlaps with that found in the adult brain, and with the expression profile of dopamine receptors both in the adult and during development.

Dopamine receptor functions: lessons from knockout mice [corrected]

In the past few years, a number of laboratories have used gene targeting via homologous recombination to generate mice deficient for key molecules involved in dopaminergic (DAergic) transmission. This tremendous effort has resulted in the successful generation and characterization of mice deficient for the neurotransmitter DA, the main terminator of DAergic neurotransmission (the DA transporter), and all five subtypes of DA receptors. This review summarizes the results from studies of the various DA receptor knockout mice and of mice deficient in proteins that mediate DA receptor signaling. It focuses on a comparison of the locomotor phenotypes and responses to drugs of abuse (psychostimulants), and reviews the results of anatomic studies examining the morphological and neurochemical differentiation of the striatum in these mutants. Moreover, an overview of recently published results highlighting the physiological relevance of the interaction between different DA receptors and between DA receptors and other neurotransmitter receptors in the modulation of behavioral and molecular responses to DAergic stimulation is presented. Finally, in view of the recently discovered heteroligomeric assemblies of neurotransmitter receptors that involve DA receptor subtypes, the potential value of knockout mice as a tool for testing the in vivo significance of these heteroligomeric receptors is discussed.

Dopamine control of striatal gene expression during development: relevance to knockout mice for the dopamine transporter

The aim of this study was to determine at which developmental stage and how dopamine regulates the expression of striatal dopamine receptor and neuropeptide mRNAs. For this, we studied the expression of these mRNAs, in relation to dopamine innervation, in normal mice from gestational day 13 (G13) to adult. Particularly, we investigated the adaptive changes in the expression of these markers in mice lacking the dopamine transporter during development. We detected tyrosine hydroxylase, by immunohistochemistry, in the ventral mesencephalon and the striatal anlage in both genotypes at G13, whereas the dopamine transporter appeared in the striatum of normal mice at G14. By in situ hybridization, we detected striatal dopamine D1, D2, D3 receptor, and substance P mRNAs at G13, preproenkephalin A mRNA at G14 and dynorphin mRNA at G17 in normal mice. Although the time of initial detection and the distribution were not affected in mutant mice, quantitative changes were observed. Indeed, D1 and D2 receptor as well as preproenkephalin A mRNA levels were decreased from G14 on, and dynorphin mRNA level was increased from G17 on. In contrast, substance P mRNA level was unaffected. Our data demonstrate that the influence of dopamine on striatal neurons occurs early during the development of the mesostriatal system as quantitative changes appeared in mutant mice as soon as G14. These findings bring new insights to the critical influence of dopamine on the expression of striatal dopamine receptor and neuropeptide mRNAs during development, and suggest that mesostriatal dopamine transmission functions from G14 on.

Developmental and age-related changes of dopamine transporter, and dopamine D1 and D2 receptors in human basal ganglia

The developmental and age-related changes of the dopamine transporter (DAT), and the dopamine D1 and D2 receptor (D1R and D2R) subtypes were investigated in basal ganglia (BG) of human brain. DAT immunostaining was mainly observed in the neuropil, neurons, and glia of the striatum. The DAT-positive neuropil was detectable at 32 GW, a peak being reached at 9-10 years of age, with a decrease to 50-63 years of age. The developmental pattern of DAT immunoreactivity in neuron was similar to that of the neuropil. DAT-positive glia were observed in the BG at 32 GW, which increased slightly at 38-40 GW, and then did not obviously change until 6-8 months after birth. D2R-positive neurons were clearly observed at 19 GW, a peak being reached at 32 GW and 1-3 months of age in the globus pallidus and striatum, respectively, with a decrease after 9-10 years of age. D1R was expressed as early as D2R, but decreased after 6-8 months. Our results suggest that D1R and D2R expression is an intrinsic property of striatal neurons and is independent of dopaminergic innervation. D1R may play a more important role in neuronal maturation of the BG than D2R. D2R may be closely correlated with late neuronal development. The higher expression of DAT during adolescence may be related to function of the BG which learns complex behavioral patterns. The significance of the age-related decreases in DAT, D1R and D2R in the BG remains to be further investigated.

Potentiation of the D2 mutant motor phenotype in mice lacking dopamine D2 and D3 receptors

Within the D2-class of dopamine receptors, the D2 and D3 subtypes share the highest degree of similarity in their primary structure. However, the extent to which these two receptor subtypes have similar or different functional properties is unclear. The present study used gene targeting to generate mice deficient for D2, D3, and D2/D3 receptors. A comparative analysis of D2 and D3 single mutants and D2/D3 double mutants revealed that D2/D3 double mutants develop motor phenotypes that, although qualitatively similar to those seen in D2 single mutants, are significantly more severe. Furthermore, increased levels of the dopamine metabolites dihydroxyphenyl acetic acid and homovanillic acid are found in the dorsal striatum of D2 single mutants. The levels of these metabolites, however, are significantly higher in mice lacking D2 and D3 receptors. In addition, results of immunoprecipitation experiments revealed that D2 single mutants express higher levels of D3 receptor proteins during later stages of their postnatal development. These results suggest that D3 receptors compensate for some of the lacking D2 receptor functions and that these functional properties of D3 receptors, detected in mice with a D2 mutant genetic background, remain masked when the abundant D2 receptor is expressed.

A developmental study of the dopamine D2R receptors in the human basal ganglia and thalamus

The development of the dopamine D2R receptors (D2R) in the human basal ganglia (BG) and thalamus was investigated in 25 normal brains by means of an immunohistochemical method and Western blotting. Immunoreactivity to D2R was detected in the cytoplasm and dendrites of small and large neurons in the BG and thalamus. D2R-positive neurons were clearly observed at 19 weeks of gestation (GW) in the globus pallidus and thalamus, and at 21 GW in the striatum. The number of D2R-positive neurons gradually increased and reached a peak at 27 GW in the globus pallidus, at 39 GW in the thalamus, and at 1 month of age in the striatum. The number of D2R-positive large neurons in the globus pallidus and small neurons in the striatum decreased after 1 year and about 10 years of age, respectively. Western blotting confirmed the specificity of the immunohistochemistry. Our results suggest that the D2R protein begins to be synthesized at an early fetal stage in the BG and thalamus, and the development of D2R is mostly consistent with neuronal maturation in the BG. D2R may play an important role in regulating the neuronal development of the BG. The decrease in D2R-positive neurons may be related to D2R post-transcriptional regulation.

Neuropathological characteristics and alteration of the dopamine D2 receptor in hypoxic-ischemic basal ganglia necrosis

The neuropathological characteristics and alteration of the dopamine D2 receptor (D2R) were investigated in 27 cases of hypoxic-ischemic basal ganglia necrosis (BGN) by means of neuropathological and immunohistochemical methods. Perinatal hypoxic-ischemic BGN manifested neuronal karyorrhexis as well as eosinophilia, karyorrhexis being more predominant in preterm infants and eosinophilia more predominant in full-term infants. Immunoreactivity to D2R was detected in the cytoplasm and dendrites of small and large neurons in the basal ganglia, and increased with neuronal maturation during the late gestational period in normal human basal ganglia. The number of D2R-positive neurons was smaller in all cases of acute BGN than that in controls, the areas of decreased D2R-positive neurons corresponding to the damaged regions observed on HE staining. Furthermore, neurons showed high expression of D2R in a few cases of remote BGN, suggesting some plasticity as to the recovery of D2R. Thus, the neuropathological characteristics of perinatal hypoxic-ischemic BGN may be related to neuronal maturation during different developmental stages in each region, and D2R development may play a role in the basal ganglia vulnerability to hypoxic-ischemia.

Distribution and postnatal ontogeny of adenosine A2A receptors in rat brain: comparison with dopamine receptors

In adult rat brain, adenosine A2A receptors and dopamine D2 receptors are known to be located on the same cells where they interact in an antagonistic manner. In the present study we wanted to examine when this situation develops and compared the postnatal ontogeny of the binding of the adenosine A2A receptor agonist [3H]CGS 21680, the binding of the dopamine D1 receptor antagonist [3H]SCH 23390 and the dopamine D2 receptor antagonist [3H]raclopride. All three radioligands bound to the striatum at birth and this binding increased several-fold during the postnatal period. [3H]SCH 23390 binding developed first (mostly during the first week), followed by [3H]raclopride binding (first to third week) and [3H]CGS 21680 binding (only during second and third week). For all three radioligands the binding tended to decrease between 21 days and adulthood. This occurred earlier and was more pronounced in the globus pallidus than in the other examined structures. The increase in [3H]CGS 21680 binding from newborn to adult was mainly due to four-fold increase in the number of binding sites. The pharmacology of [3H]CGS 21680 binding to caudate-putamen was similar in newborn, one-week-old and adult animals, and was indicative of A2A receptors. The binding was inhibited by guanylyl imidodiphosphate at all ages, indicating that A2A receptors are G-protein-coupled already at birth. In contrast to the large increase in [3H]CGS 21680 binding, there was a decrease in the levels of A2A messenger RNA during the postnatal period in the caudate-putamen. In cerebral cortex [3H]CGS 21680 bound to a different site than the A2A receptor. From birth to adulthood cortical binding of [3H]CGS 21680 increased four-fold and that of the adenosine A1 agonist [3H]cyclohexyladenosine 19-fold. During early postnatal development [3H]SCH 23390 binding was higher in deep than in superficial cortical layers, but this difference disappeared in adult animals. There was binding of both [3H]CGS 21680 and [3H]cyclohexyladenosine to the olfactory bulb, suggesting a role of the two adenosine receptors in processing of olfactory information. [3H]CGS 21680 binding was present in the external plexiform layer and glomerular layer, and increased during development, but the density of binding sites was about one tenth of that seen in caudate putamen. [3H]cyclohexyladenosine showed a very different labelling pattern, resembling that observed with [3H]SCH 23390. Postnatal changes in adenosine receptors may explain age-dependent differences in stimulatory caffeine effects and endogenous protection against seizures. Since A2A receptors show a co-distribution with D2 receptors throughout development, caffeine may partly exert such actions by regulating the activity of D2 receptor-containing striatopallidal neurons.

Codistribution of the dopamine D3 receptor and glucocorticoid receptor mRNAs during striatal prenatal development in the rat

Glucocorticoids and dopamine (DA) may affect brain development and permanently programme central nervous system (CNS) responses. The ontogeny of the striatal glucocorticoid receptor (GR) mRNA and of DA D1, D2 and D3 receptor subtype mRNAs were, therefore, studied by means of in situ hybridization techniques. The expression of GR and the dopamine D3 receptor mRNAs but not of DA D1 and D2 receptor subtype mRNAs were observed in the striatal neuroepithelium during all prenatal stages studied (E14.5-E20.5). These results suggest that GR may directly influence striatal developmental processes, possibly involving the dopamine D3 receptor.

Molecular anatomy of the development of the human substantia nigra

A series of 15 fetal and perinatal human brains (from week 12 of fetal life to day 2 after birth) was studied in order to describe the anatomical and molecular correlates of the substantia nigra ontogeny. In situ hybridization, immunohistochemistry and binding studies were used to detect D2 dopamine receptor (D2R) mRNA, D2R binding sites, dopamine membrane transporter (DAT) mRNA, tyrosine hydroxylase (TH) protein D1 dopamine receptor (D1R) protein and D1R binding sites. Dopaminergic (DA) neurons of the substantia nigra were detected through TH immunoreactivity from week 12. At week 16, the substantia nigra was clearly delineated as a compact group of intermingled neurons and fibers. From week 19, groups of DA neurons were segregated from the pars reticulata. These groups have been divided into the substantia nigra pars compacta, the ventral tegmental area and the retrorubral area. The DA neurons exhibited a gradual increase in size and branching development until birth. From week 12 onward they expressed several other markers of dopamine transmission, i.e., D2R mRNA, D2R binding sites and DAT mRNA. The ventral tegmental area expressed lower levels of mRNA for DAT and D2R than the pars compacta. From week 12, D1R immunoreactivity and D1R binding sites were also present in the substantia nigra pars reticulata. This suggests that projecting striatonigral neurons, known to express the D1R gene, have developed pathways connecting with the substantia nigra by week 12. Our results demonstrate that the developing substantia nigra in human displays early transcriptional and translational activity for the main constituents of dopaminergic transmission from week 12 and receives at this time dopaminoceptive inputs bearing D1 receptors from the striatum.

The temporal evolution of striatal dopamine receptor binding and mRNA expression following hypoxia-ischemia in the neonatal rat

Neonatal hypoxic-ischemic (HI) brain injury in the rat alters dopamine receptors. To determine whether such changes are permanent, dopamine receptors and corresponding mRNA were examined at various time points after neonatal HI using receptor autoradiography and in situ hybridization. Rat pups underwent ligation of the left common carotid artery followed by hypoxic exposure (8.5% O2 for 3 h). Controls underwent sham surgery alone. Animals surviving for 2-80 days following HI were studied. Striatal D1 receptors (labeled by [3H]SCH23390) were reduced as early as 2 days following HI, remained depressed for 21 days, but recovered to control levels by young adulthood (3 months of age). D2 receptors (labeled by [125I] iodosulpride) did not decline until 10 days after HI, and remained uniformly depressed throughout the caudate-putamen thereafter. Changes in D1 receptor mRNA transcripts closely paralleled alterations in receptors: early reductions in D1 mRNA signal recovered by young adulthood. D2 mRNA exhibited a unique temporal profile with an early decrease (2 days following HI), and prompt, persistent recovery. Dopamine receptors and transcripts are differentially affected by HI injury early in development. Whereas D1 receptor expression recovers from neonatal HI injury, D2 receptors remain permanently affected despite the presence of normal levels of D2 receptor transcripts. A persistent, post-transcriptional effect of HI on D2 receptor expression is suggested.

Postnatal development of the dopamine transporter: a quantitative autoradiographic study

The dopamine transporter performs an important role in regulating neurochemical transmission at dopaminergic synapses, as well as dopamine synthetic activity in dopaminergic neurons. Certain drugs and toxins exert effects at the transporter, especially cocaine, a common drug of abuse. We studied the development of these sites in the rat at postnatal ages day 0, 5, 10, 15, 21 and adult using quantitative autoradiography with the cocaine analogue [125I]RTI-55. At birth, certain structures such as the substantia nigra, interstitial nucleus of the medial longitudinal fasciculus, frontal and parietal cortex, and substantia inominata had [125I]RTI-55 binding levels that were already near the adult value. The striatum developed later, showing earlier growth in the anterior and dorsolateral regions, with early localization in both striosomes and a subcallosal streak. Anterior-to-posterior and lateral-to-medial gradients were present at day 0. The anterior striatum, ventral tegmental region, substantia nigra compacta and bed nucleus of the stria terminal is showed transient peaks in binding levels that were higher than the adult values. Structures showing relatively late development included the prefrontal cortex, nucleus accumbens shell, olfactory tubercle and subthalamic nucleus. Knowledge of the differential developmental patterns of the dopamine transporter in different brain regions may have implications for understanding the neurodevelopmental effects of prenatal cocaine exposure.

Functional and molecular differentiation of the dopamine system induced by neonatal denervation

The administration of the neurotoxin 6-hydroxydopamine (6-OHDA) to damage the mesostriatal dopamine (DA) system in the neonate results in different neurochemical and behavioral consequences as compared to lesions made in adulthood. There have been few direct data to support the conclusion that the behavioral changes following neonatal 6-OHDA lesions reflect plasticity of the DA system. It is our hypothesis that the plasticity of the developing DA system is fundamentally different from that of the adult. Responses to 6-OHDA lesions can only be understood within the context of the status of the mesostriatal DA system at the time of the lesion. There are stages of development in the early postnatal period when certain components of the mesostriatal DA system are differentially sensitive to 6-OHDA lesions. These "windows" of vulnerability can be predicted from an analysis of the developmental expression of DA receptors and the maturation of the subpopulation of the mesostriatal DA system that innervates them. We review the differences in the behavioral plasticity of the adult and neonate sustaining 6-OHDA lesions to the mesostriatal DA system, the mechanisms responsible for the behavioral plasticity in the adult, and our conceptualization of which mechanisms are affected in the neonate.

Neonatal 6-hydroxydopamine lesions lead to opposing changes in the levels of dopamine receptors and their messenger RNAs

Previous studies have established that selective damage to the early-developing components of the mesostriatal dopamine system produces profound changes in dopamine D1 receptor-mediated behaviors, while decreasing D1 receptor density. In order to better understand the effects of early intrastriatal 6-hydroxydopamine lesions, we studied the ontogenetic expression (postnatal days 7, 14, 35 and 90) of D1 and D2 receptors, and their corresponding messenger RNAs, in rats that had received intrastriatal 6-hydroxydopamine or vehicle lesions on postnatal day 1. Using receptor autoradiography, significant (P < 0.05) decreases in [3H]SCH 23390 binding to D1 receptors in the rostral and caudal dorsomedial and ventromedial caudate of 6-hydroxydopamine-lesioned animals were evident by postnatal day 7, and remained depressed at all future time points. A significant decrease in D1 receptor concentration occurred in the dorsolateral caudate at later time points (postnatal days 35 and 90). [3H]Spiperone binding to D2 receptor sites was unchanged throughout the entire study. In situ hybridization for D1 and D2 messenger RNA expression showed contrasting results. 6-Hydroxydopamine induced significant decreases of D1 messenger RNA levels in the dorsolateral and dorsomedial caudate by postnatal day 7. By postnatal day 14, messenger RNA expression was significantly elevated in the dorsomedial and ventromedial caudate of the 6-hydroxydopamine group, and remained elevated thereafter. D1 messenger RNA levels became elevated in the lateral caudate at later time points (postnatal days 35 and 90). The opposing changes in D1 receptor concentrations and the messenger RNA encoding the protein did not occur as a consequence of increased transport of D1 receptors to striatonigral terminals. D2 messenger RNA levels in the dorsal caudate were significantly decreased on postnatal day 7, and became higher than controls at postnatal day 14, but were unchanged from controls at later time points. Together, the D1 receptor and D1 messenger RNA findings suggest that the normal relationship between levels of D1 receptor transcript and D1 receptor protein is permanently altered following the early loss of dopamine. In contrast, the results indicate that dopamine plays a minor role in the early postnatal development of the D2 receptor protein and transcript. These findings suggest that dopamine may be involved in the coordinated expression of some dopamine receptors and their corresponding messenger RNAs during development.

Dopaminergic control of gene transcription during striatal ontogeny: c-fos induction by D1 receptor activation in the developing striosomes

During striatal development, dopamine afferents initially reach the striosomal compartment, and this early dopamine innervation is thought to influence, through the D1 receptors first expressed in the developing patches, the phenotype of target striatal cells. Dopaminergic control of gene expression during ontogeny could be mediated by transcription factors such as c-fos, whose expression is regulated by synaptic signals. However, in the striatum of intact adult animals, D1 dopamine agonists fail to induce c-fos expression. The c-fos response to D1 receptor activation in adults requires a previous sensitization of dopaminergic receptors by chronic treatment with reserpine or by lesion of the nigro-striatal pathway. In this work, we investigated through in situ hybridization the ability of striatal cells to express c-fos messenger RNA (mRNA) in response to the D1 agonist SKF 38393 (4 to 8 mg/kg) in developing mice. During a transient postnatal period, c-fos expression in a patchy distribution was induced by D1 receptor activation: only a faint response was detected on postnatal day 1, but islands of strong hybridization signals for c-fos mRNA in response to the D1 agonist were observed at postnatal day 3, with a progressive decrease in intensity from day 6 to day 15. The distribution of this transient c-fos response corresponded to the early striosomal compartment since it matched with the regions of intense mu-opioid and dopamine-D1 receptor binding, as assessed by autoradiography performed on adjacent sections. By day 21, as in adult animals, no more c-fos response to D1 agonists was observed, except in the most caudal division of the striatum. Strong expression, which persisted into adulthood, was detected in this region from the third postnatal day. This induction of striatal c-fos expression by D1 agonists during early postnatal development is indicative of an enhanced sensitivity of D1 receptors or of D1-associated transduction pathways compared to the adult pattern, and suggests a possible role for dopamine-controlled c-fos gene expression in the development of target striatal neurons during this critical period.

Substance P phenotype defines specificity of c-fos induction by cocaine in developing rat striatum

Activation of c-fos, a member of the class of immediate early genes that act as transcription factors, may be one of the initial molecular mechanisms underlying plastic changes in gene expression in response to drugs of abuse. By combining c-fos (radioactive) in situ hybridization histochemistry with nonradioactive in situ hybridization histochemistry for mRNAs encoding other striatal markers [preprotachykinin (substance P), proenkephalin, and D1 and D2 receptors], we have identified the cellular phenotype of striatal neurons activated by acute administration of cocaine to P8, P15, P28, and adult rats. At each age examined, substance P+, enkephalin- striatal neurons were the predominant class of cells in which cocaine induced c-fos gene expression. In addition, the topography of cellular activation at each age examined was distinct and reflected the topography of distribution of cells expressing high levels of substance P mRNA. We conclude that there is a marked specificity of cellular activation in striatum following acute cocaine administration restricted predominantly to subsets of substance P-expressing cells, with age-specific patterns in their topographic distribution.

Ontogeny of glucocorticoid and D2 receptors in the rat pituitary: an in situ hybridization study

The expression of glucocorticoid and D2 dopamine receptors (GR and D2R) during rat pituitary ontogenesis was studied by in situ hybridization (ISH). On early stages, E13-E14, a weak specific signal for GR mRNA was obvious in the whole Rathke's pouch (RP) whereas subsequently, from E17-E18, strong labelling was restricted to the anterior lobe (AL) and the neural lobe (NL). At the same time, D2R mRNAs appeared in the intermediate lobe (IL) and the long isoform of the D2R (D2R 444) was detectable with specific probes. On the postnatal stages, until adult, GR mRNA, if present, was always undetectable in the IL using the conventional ISH technique. These data indicate a possible early regulation of POMC gene expression by glucocorticoid in corticotrophic cells of the AL and by dopamine in the melanotrophic cells of the IL. The possibility of a negative regulation of GR mRNA by dopamine (DA) in the IL as soon as E17 is discussed.

Ontogeny of D1A and D2 dopamine receptor subtypes in rat brain using in situ hybridization and receptor binding

The prenatal and postnatal ontogeny of D1A and D2 dopamine receptors was assessed by in situ hybridization of messenger RNAs encoding the receptors and by radioligand binding autoradiography. On gestational day 14, signals for D1A and D2 dopamine receptor messages were observed in selected regions in ventricular and subventricular zones which contain dividing neuroblasts, and in intermediate zones that contain maturing and migrating neurons. Specifically, D1A and D2 dopamine receptor message was observed in the developing caudate-putamen, olfactory tubercle, and frontal, cingulate, parietal and insular cortices. Additionally, D1A dopamine receptor messenger RNA was found in the developing epithalamus, thalamus, hypothalamus, pons, spinal cord and neural retina; D2 dopamine receptor messenger RNA was also observed in the mesencephalic dopaminergic nuclear complex. Gene expression of D1A and D2 dopamine receptor subtypes in specific cells as they differentiate precedes dopamine innervation and implies that receptor expression is an intrinsic property of these neurons. The early expression of dopamine receptor messenger RNA suggests a regulatory role for these receptors in brain development. While the signal for both messages increased in the intermediate zones on gestational day 16, it decreased in the ventricular and subventricular zones, and was no longer apparent in these zones by gestational day 18. By gestational day 18, abundant D1A or D2 dopamine receptor messenger RNA was observed in cell groups similar in location to those observed in the adult brain. On gestational day 18, D1A dopamine receptor message was noted in the neural retina, anterior olfactory nucleus, the insular, prefrontal, frontal, cingulate, parietal and retrosplenial cortices, the olfactory tubercle, caudate-putamen, lateral habenula, dorsolateral geniculate nucleus, ventrolateral and mediolateral thalamic nuclei, and the suprachiasmatic and ventromedial nuclei of the hypothalamus. D2 dopamine receptor message was observed on gestational day 18 in the insular, prefrontal, frontal and cingulate cortices, the olfactory tubercle, caudate-putamen, ventral tegmental area, substantia nigra, and the intermediate lobe of the pituitary. At birth, expression of messenger RNA for both dopamine receptor subtypes in the striatum approximated that seen in mature rats. In contrast, D1A and D2 receptor binding, measured with [3H]SCH-23390 and [3H]raclopride, respectively, was low at birth and progressively increased to reach adult levels between days 14 and 21. The in situ hybridization data showing early prenatal expression of messenger RNA for the D1A and D2 dopamine receptors are consistent with the hypothesis that these receptors have a regulatory role in neuronal development.(ABSTRACT TRUNCATED AT 400 WORDS)

Prenatal neuroleptic exposure and growth stunting in the rat: an in vivo and in vitro examination of sensitive periods and possible mechanisms

There is increasing evidence that a number of neurotransmitters can play a trophic role in the development of the central nervous system. Dopamine is one candidate for this role. In a series of papers, Lewis, Patel, and colleagues have demonstrated that exposure to compounds which interfere with dopaminergic neurotransmission ("neuroleptics") can block cell proliferation in the brains of 11-day-old rat pups for at least 24 hr. More recently our laboratory has reported that prenatal exposure to haloperidol (HAL), a neuroleptic which binds to and blocks dopamine receptor sites in the adult brain, permanently stunts body and brain growth when that exposure extends throughout postimplantation pregnancy. Reported here are the results of two experiments conducted to further examine this phenomenon. The first experiment attempted to identify sensitive gestational periods for the HAL effect on growth in vivo. This experiment also assessed the effect of exposure to reserpine (RES), a compound which in the adult blocks dopaminergic neurotransmission by rupturing monoamine storage vesicles, an effect which is quite distinct from the HAL mechanism of action. In a second experiment, gestational day (GD) 9 embryos were exposed in vitro for 48 hr to either HAL, RES, or one of two specific blockers of dopamine receptor subtypes. Schering 23390 (SCH) was used as the D1 blocker, and sulpiride (SULP) as the D2 blocker. The in vivo experiment showed that twice-daily exposure to subcutaneous injections of HAL (5 mg/kg for each of the 2 injections) or RES (0.1 mg/kg for each injection) permanently stunted brain growth when injections were given in midpregnancy (GD 12-16), but not in late pregnancy (GD 16-20). RES was substantially more fetotoxic than HAL, especially late in pregnancy. The growth stunting produced by either compound with GD 12-16 exposure was not restricted to dopamine-rich areas of the brain, or indeed to the brain itself, in that body weight was also depressed. Pair-fed controls did not show the same magnitude or duration of stunting, indicating that this effect was not due to drug-induced maternal hypophagia. The in vitro experiment revealed that exposure to micromolar concentrations of any of the 4 neuroleptics reduced embryonic GD 11 DNA and protein content and delayed development. HAL and SCH had the most pronounced effects at concentrations close to blood levels reportedly produced by exposure to doses used in the in vivo experiments. RES was less potent, and SULP still less potent than RES.(ABSTRACT TRUNCATED AT 400 WORDS)

Transcription of the rat dopamine-D2-receptor gene from two promoters

Modulation of the expression of the D2-dopamine receptor gene is involved in several pathological and developmental circumstances. The gene and the corresponding promoter regions of the rat D2 receptor were isolated and partly characterized to study its regulation. The rat D2-receptor gene spans at least 50 kb, and possesses eight exons; its organization was compared to those of the other dopamine-receptor genes in a phylogenetic perspective. The gene contains two transcription-start sites: the major one is located about 320 bp upstream from the 3' end of the first exon, and a minor site is 70 bp further upstream. Transient-expression assays with fusion constructs comprising fragments of the D2-promoter region and the luciferase reporter gene confirmed the existence of two independent, TATA-lacking promoters. Both promoters separately induced transcription of the luciferase gene in C6 glioma, primary fibroblasts, GH3 and MMQ pituitary cell lines, among which only the MMQ cells normally express the D2 receptor. Transcription is enhanced by the reunion of the two promoters, and modified by the addition of upstream sequences. Thus the 1-kb promoter region analysed does not contain all the elements necessary to confer tissue-specific expression of the gene, but does carry some positive and negative regulatory elements, which remain to be characterized.

Prenatal ontogeny of D2 dopamine receptor and dopamine transporter gene expression in the rat mesencephalon

This work demonstrates the early prenatal expression (by gestational day 14) of dopamine D2 receptor and dopamine transporter mRNAs by immature dopaminergic cells of the rat mesencephalon using in situ hybridization. Our results indicate that mRNAs are detectable 3 days before the appearance of functional D2 presynaptic receptors and detectable dopamine release at striatal terminals.

A2a adenosine receptor gene expression in developing rat brain

Adenosine is a neuromodulator in the adult central nervous system. Membrane-bound receptors for adenosine have been identified and cDNAs for A1, A2a, A2b, and A3 adenosine receptor subtypes have been cloned recently. The present study documents the developmental appearance of A2a adenosine receptor gene expression in the rat brain. In situ hybridization using 35S-labeled RNA probes generated from the rat A2a adenosine receptor cDNA revealed receptor gene expression in the striatum on gestational day (GD) 14. Developmental alterations in the pattern of receptor gene expression within the striatum suggest that this receptor mRNA is expressed by striatal neurons soon after they complete neurogenesis. Transient expression of the A2a adenosine receptor mRNA was observed in cerebral cortex, subiculum, parafascicularis nucleus of the thalamus, facial nucleus, trigeminal nucleus, locus coeruleus, area postrema, anterior pituitary gland and in the fetal cerebral vasculature. The ganglia of cranial nerves V, VII, VIII, IX and X expressed A2a adenosine receptor mRNA in fetuses; adults have not been examined. A2a adenosine receptor mRNA was expressed in the carotid body and intermediate lobe of the pituitary during development and also in adult rats. Northern blot analysis revealed that the A2a adenosine receptor transcript is consistent in size (ca 2.5 kb) across the developmental period examined (GD 14 through adult). Previous studies in adult rats have reported that A2a adenosine receptor gene expression is limited to a population of striatal medium spiny neurons. This study documents early developmental expression of the A2a adenosine receptor gene in the striatum and its transient expression elsewhere in the brain and cerebral vasculature. If the A2a adenosine receptor mRNA is translated into receptor protein shortly after the mRNA is expressed, adenosine could influence neuronal differentiation, migration, synaptogenesis, and angiogenesis. Expression of A2a adenosine receptor mRNA in cranial ganglia, carotid body, and intermediate lobe of the pituitary gland similarly suggests novel sites of adenosine action during development and in the adult.

Prenatal D1, D1b and D3 dopamine receptor gene expression in the rat forebrain: detection by reverse polymerase chain reaction

Three dopamine receptor mRNAs were detected by reverse polymerase chain reaction in the rat forebrain during ontogeny. The D1 receptor mRNA gave a faint signal from gestational day 11 (G11) on, while the D1b receptor was not detectable before G12. The D3 receptor mRNA was slightly expressed at G11 and clearly present at G14. Our results show that these mRNAs are present at early stages of fetal life, each one with its specific time of appearance.

Fetal behavior and the dopamine system: activity effects of D1 and D2 receptor manipulations

Binding studies have indicated that D1 and D2 dopamine receptor subtypes are present in rats before birth, but it is not known whether these receptors are functional during the prenatal period. In the present study, day-21 rat fetuses were prepared for direct observation after pharmacological manipulation of D1 and/or D2 receptors. The D1 agonist SK&F38393 induced a marked increase in fetal activity (i.e., forelimb, rearlimb, and head movements) while the D2 agonist quinpirole produced a slight suppression in activity. Coadministration of both agonists resulted in low levels of fetal activity, suggesting an interaction between D1 and D2 receptors. Administration of the D2 antagonist sulpiride resulted in little change in fetal behavior but was effective in blocking the behavioral activation induced by the D1 agonist. The D1 antagonist SCH23390, administered alone or in combination with the D2 antagonist, produced a modest increase in fetal activity that included mouthing and facial wiping behavior. These data provide evidence that the dopamine system is functional and capable of mediating behavioral effects in the near-term rat fetus. Further, manipulation of dopamine receptors results in a different pattern of behavioral effects than has been reported in older animals. The observation that fetal behavior is influenced by these pharmacological challenges suggests that drugs of abuse known to affect the dopamine system, such as cocaine, may cause profound changes in fetal behavior in utero that could consequently lead to alterations in behavioral and CNS development.

Dopamine decreases striatal enkephalin turnover and proenkephalin messenger RNA abundance via D2 receptor activation in primary striatal cell cultures

Dopaminergic regulation of striatal enkephalin biosynthesis and secretion was studied in primary neuronal cultures from fetal rat striatum. To allow pharmacological treatment, striatal primary cell cultures were seeded in chemically defined medium onto extracellular matrix. In these conditions, pharmacological treatment of the striatal neurons on the 10th day in vitro for 48 h with 10(-6) M dopamine induced a 50% decrease in preproenkephalin mRNA level concomitant with a 50% decrease in methionine enkephalin neuronal content. These effects of dopamine were mimicked by the D2 agonist bromocriptine (10(-6) M). The decrease in methionine enkephalin neuronal content induced by dopamine or bromocriptine was reversed by the simultaneous application of sulpiride (10(-6) M), a selective D2 antagonist. Interestingly, the D1 agonist SKF 38393 (10(-6) M) application for 24 or 48 h was found to have no significant effect on methionine enkephalin neuronal content. To ensure dopamine regulation of enkephalin secretion, shorter dopaminergic treatments were performed. Dopamine application (10(-6) M) for 2 h had no significant effect on basal methionine enkephalin secretion but significantly decreased (50%) methionine enkephalin secretion induced by KCl 56 mM. This effect of dopamine on the KCl-induced methionine enkephalin secretion was mimicked by bromocriptine (10(-6) M), reversed by sulpiride (10(-6) M) and unaffected by the D1 antagonist SCH 23390 (10(-6) M) application onto striatal neurons. Our data provide direct evidence for a dopaminergic inhibitory control on enkephalin biosynthesis and secretion from striatal cell cultures, mediated through the dopaminergic D2 receptor activation.

Ontogeny of the proenkephalin system in the rat corpus striatum: its relationship to dopaminergic innervation and transient compartmental expression

The earliest detection of the proenkephalin gene was on embryonic day 16 in neuronal cell bodies in the ventrolateral portion of the caudal neostriatum. This expression was identified by both immunocytochemistry for synenkephalin, the nonopioid N-terminus of proenkephalin (1-70), and preproenkephalin in situ hybridization with a complementary DNA probe. Two developmental gradients of preproenkephalin expression and synenkephalin immunoreactivity were observed: (i) a ventrolateral to dorsomedial and caudal to rostral gradient in the rostral caudate-putamen; and (ii) a ventromedial to dorsolateral and rostral to caudal gradient in the caudal caudate-putamen. Ventrolateral to dorsomedial and caudal to rostral developmental gradients of synenkephalin fiber immunoreactivity were also identified in the globus pallidus. Methionine enkephalin immunoreactivity was not consistently detectable until postnatal day 10 and 15 in the rostral and caudal globus pallidus, respectively. A transient patchy distribution of increased preproenkephalin expression from embryonic day 20 through postnatal day 5 occurred. These patches and a subcallosal streak were found to overlap partially with areas of increased tyrosine hydroxylase immunoreactivity by adjacent section analyses. The earliest detection of tyrosine hydroxylase immunoreactivity was found to coincide with that of proenkephalin on embryonic day 16, but in differing regions of the corpus striatum. Tyrosine hydroxylase immunoreactivity in the rostral caudate-putamen preceded, while in the caudal caudate-putamen it followed first expression of the proenkephalin gene. Early proenkephalin expression, by both synenkephalin immunocytochemistry and preproenkephalin in situ hybridization, was also detected in the central nucleus of the amygdala on embryonic day 16 immediately ventral to the area of expression in the caudate-putamen. Preproenkephalin expression in the olfactory tubercle and nucleus accumbens first appeared on embryonic day 20 and expression proceeded in a lateral to dorsomedial gradient continuous with the ventral part of the rostral caudal-putamen. Relatively late detection of methionine enkephalin immunoreactivity in comparison to synenkephalin possibly indicates a developmental delay in the complete enzymatic processing of the proenkephalin precursor. Differing gradients in the ontogeny of preproenkephalin expression in the rostral vs the caudal caudate-putamen suggest possible anatomical and developmental differences of these two regions. Also, transient compartmentalization of preproenkephalin expression and differences in dopaminergic innervation as detected by tyrosine hydroxylase immunoreactivity were further support for the existence of two subsets of proenkephalinergic neurons in the caudate-putamen. Contemporaneous development of preproenkephalin expression and synenkephalin immunoreactivity in the central nucleus of the amygdala with the ventral part of the caudal caudate-putamen also suggested developmental homology.(ABSTRACT TRUNCATED AT 400 WORDS)

D2-dopaminergic agonist quinpirole and 8-bromo-cAMP have opposite effects on Go alpha GTP-binding protein mRNA without changing D2 dopamine receptor mRNA levels in striatal neurones in primary culture

Long-term coordinated regulations (during development or by agonists and second messenger molecules) of the expression of mRNAs encoding D2-dopamine (DA) receptors and D2 receptor-linked Go alpha proteins have been studied by Northern blot analysis in mouse embryonic striatal neurones in primary culture. During the course of the cell culture, the levels of both mRNAs increased, in conjunction with the maturation of the neurones. When the preparation was treated with the D2-DA agonist quinpirole (5-15 hrs, 10(-4) M), which decreases cAMP in these neurones, the levels of Go alpha mRNAs were enhanced whereas that of the D2 mRNA remained unchanged. Conversely, the Go alpha mRNAs, but not the D2 mRNA, decreased when the neurones were exposed to 8-bromo-cAMP (16 hrs, 10(-6) M). It is concluded that, in these experimental conditions where neurones have not yet established their connexions, the longterm regulation of the membrane transmission of D2-DA signal might implicate mainly the Go alpha encoding gene.

Expression of the HBNF (heparin-binding neurite-promoting factor) gene in the brain of fetal, neonatal and adult rat: an in situ hybridization study

HBNF (heparin-binding neurite-promoting factor) and MK (midkine) are members of a newly recognized family of proteins, the expression of which is developmentally regulated. These proteins are expressed highest during fetal development in many tissues but they seem to be rather restricted to the brain in adult animals. Gene expression for these proteins is inducible by retinoic acid in embryonal carcinoma cell lines. They induce neurite outgrowth in cultured neurons, and they are characterized by high sequence conservation between species. While the function(s) of these proteins are unknown, available evidence suggests possible roles in the development and the maintenance of neural tissues. This in situ hybridization study investigates the temporal and spatial expression pattern of the HBNF gene in the brain of developing rats. The HBNF gene is highly expressed in the neuroepithelium and the ependyma from fetal day 15 on. Although most ependymal structures express the gene strongly, a few restricted areas of the ependyma do not express HBNF (ventral part of the fourth ventricle, subcommissural organ). In the brain parenchyma, HBNF is expressed in the thalamo-hippocampal area from fetal day 15 and in the cerebral cortex from fetal day 16, with high expression occurring in the superficial layers of the cortex. The nature of the cells expressing the gene, while difficult to ascertain, is probably glial for the most part. However, certain neurons (in limited areas of the brain parenchyma) and most pial cells (in the meninges), also express the gene. HBNF gene expression decreases sharply a few days after birth. HBNF mRNA is also detectable at fetal days 15 and 16 in the face fetal mesenchyma. In the adult rat brain, the expression of the HBNF gene appears to be restricted to neurons of the hippocampus and of the olfactory bulb and to the superficial layers of the cortex. The structurally related MK gene, though not extensively studied here, shows an entirely different temporal and spatial expression pattern. MK gene is weakly expressed during ontogeny in most brain areas, and in the adult animal, MK mRNA is present only in the choroid plexus. The intense and widely distributed expression of the HBNF gene in several cell populations in the fetus, the progressive spatial and quantitative restriction of HBNF gene expression with brain differentiation, as well as the properties of the protein suggest important and diverse functions for HBNF in cellular interactions and cell differentiation in the developing brain, that must act temporally and spatially by ways distinct from its MK companion molecule.

Ontogeny of gene expression of adenosine A2 receptor in the striatum: early localization in the patch compartment

The ontogeny of adenosine A2 receptor mRNA and adenosine A2 binding sites distributions was studied by in situ hybridization histochemistry and receptor autoradiography in pre- and post-natal rat striatum, postnatal dog striatum, and a human fetus striatum and compared to that of dopamine D1 and mu opiate receptors. The early postnatal striatum demonstrated heterogeneous distributions of adenosine A2 receptor mRNA and adenosine A2 binding sites with patches of dense labeling corresponding to dopamine D1 and mu opiate receptors enriched zones. This patchy pattern evolved to the homogeneous distribution observed in the adult. The higher intensity of adenosine A2 receptor mRNA enriched patches correspond at the microscopical level to a higher density of labeled neurons in the patches areas and also to a higher level of expression per labeled patches neuron than in the matrix ones. This demonstrates for the first time that differences in patch/matrix receptor density is at least partly linked to different levels of receptor gene expression.

Ontogeny of dopamine D2 receptor mRNA in rat brain

The postnatal development of rat brain dopamine D2 receptor gene expression was investigated in animals 1 day to 1 year old. The level of expression of the striatal D2 mRNA was appreciable at birth (day 1), steadily increased to a maximum at day 28, and showed declines at ages 6 months and one year. The mRNA development profile was similar to that of [3H]spiroperidol binding in striatal membranes except that there was a lack of correlation between mRNA levels and [3H]spiroperidol binding during the early developmental periods. For example, although the mRNA expression at day 1 is about 75% of the 28-day value, the corresponding level of [3H]spiroperidol binding is only 15% of the value observed at day 28. Polymerase chain reaction (PCR) analysis of alternatively spliced forms of D2 receptor mRNA showed that the developmental expression of the two isoforms proceeded in parallel as the ratio of D2L and D2S mRNAs remained more or less constant in different age group of rats. In situ hybridization revealed a differential developmental profile of D2 mRNA for major dopaminergic regions of rat brain such as caudate putamen, nucleus accumbens, olfactory tubercle and substantia nigra.

Ontogeny of D1 and DARPP-32 gene expression in the rat striatum: an in situ hybridization study

D1 dopamine receptor (D1R) and DARPP-32 (a dopamine and adenosine 3',5'-monophosphate regulated phosphoprotein), gene expression was studied in the rat striatum in adults and during ontogeny by in situ hybridization. D1R mRNA was first detected in the striatal primordium at day 17 of gestation. At day 18, D1R mRNA was found throughout the striatum. Before birth, the striatal neurons had neuroblastic aspect and were close together, giving homogeneous and compact labelling. After birth, the topography and aspect of the neurons containing D1R mRNA and DARPP-32 mRNA were similar. The two mRNAs were detectable in the caudate-putamen, accumbens nucleus and olfactory tubercle. The microautoradiographic analysis demonstrated that D1R and DARPP-32 genes are massively expressed by the medium-sized striatal neurons. The proportion of medium-sized neurons containing the DARPP-32 mRNA was however higher than that of the neurons containing the D1R mRNA. Furthermore, an unexpected proportion of large-sized neurons express these genes. This proportion varies with development. Comparison between the appearance, topography and frequency of choline-acetyltransferase immunoreactive neurons and large-sized neurons containing D1R or DARPP-32 mRNA suggest that these large-sized neurons containing D1R and DARPP-32 mRNAs are cholinergic ones.

Striatal neurons express increased level of dopamine D2 receptor mRNA in response to haloperidol treatment: a quantitative in situ hybridization study

In the present study, quantitative in situ hybridization was used to analyse the effect of haloperidol treatment on D2 dopamine receptor gene expression in the rat caudate-putamen nucleus. Variations of D2 receptor mRNA level were studied and measured at the macroscopic level of densitometric analysis of X-ray film and at the microscopic level by counting of autoradiographic silver grains in striatal cells. Macroscopic analysis demonstrated that haloperidol treatment two times 1 mg/kg per day during seven, 14 and 21 days increased D2 receptor mRNA level in the caudate-putamen. Detailed microscopic analysis demonstrated a significant increase in D2 receptor mRNA in the two neuronal populations known to express the D2 receptor gene: medium-sized neurons previously identified as enkephalinergic neurons, and large-sized neurons previously identified as cholinergic neurons. The increase was more important in cholinergic neurons (+119%) than in enkephalinergic neurons (+54%). Haloperidol treatment did not modify the number of medium-sized enkephalinergic neurons expressing the D2 receptor mRNA. In contrast, it significantly increased the percentage of large-sized neurons containing D2 receptor mRNA (from 80 to 94%). These results demonstrate that haloperidol treatment acts at the gene level to modulate D2 receptor content in striatal dopaminoceptive neurons, and that the D2 receptor mRNA increase in postsynaptic neurons contributes to dopamine supersensitivity induced by neuroleptics in the rat. This suggests that dopamine acts trans-synaptically to control D2 receptor gene expression in target striatal neurons. These results suggest that modifications of D2 receptor gene expression may be part of the biological events that lead to the movement disorders induced by neuroleptic drugs or Parkinson's disease.